These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 15588872)

  • 1. Results of a phase I study to dose escalate using intensity modulated radiotherapy guided by combined PET/CT imaging with induction chemotherapy for patients with non-small cell lung cancer.
    Holloway CL; Robinson D; Murray B; Amanie J; Butts C; Smylie M; Chu K; McEwan AJ; Halperin R; Roa WH
    Radiother Oncol; 2004 Dec; 73(3):285-7. PubMed ID: 15588872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy.
    Onimaru R; Fujino M; Yamazaki K; Onodera Y; Taguchi H; Katoh N; Hommura F; Oizumi S; Nishimura M; Shirato H
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):374-81. PubMed ID: 18029106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
    Yom SS; Liao Z; Liu HH; Tucker SL; Hu CS; Wei X; Wang X; Wang S; Mohan R; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2007 May; 68(1):94-102. PubMed ID: 17321067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of radiation pneumonitis: dose-volume histogram analysis in 62 patients with non-small cell lung cancer after three-dimensional conformal radiotherapy.
    Piotrowski T; Matecka-Nowak M; Milecki P
    Neoplasma; 2005; 52(1):56-62. PubMed ID: 15739028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of hyperfractionated accelerated radiotherapy (HART) after induction cisplatin (CDDP) and vinorelbine (VNR) for stage III non-small-cell lung cancer (NSCLC).
    Ishikura S; Ohe Y; Nihei K; Kubota K; Kakinuma R; Ohmatsu H; Goto K; Niho S; Nishiwaki Y; Ogino T
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1117-22. PubMed ID: 15752891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction therapy of loco-regional non-small-cell lung cancer with reliable response and low toxicity (low dose radiotherapy sensitizes tumor to subsequent chemotherapy?).
    Takita H; Shin KH; Soh AY; Yi WS; Wilding G
    Lung Cancer; 2009 Mar; 63(3):387-92. PubMed ID: 18676056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose heterogeneity in the target volume and intensity-modulated radiotherapy to escalate the dose in the treatment of non-small-cell lung cancer.
    Schwarz M; Alber M; Lebesque JV; Mijnheer BJ; Damen EM
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):561-70. PubMed ID: 15890601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereotactic hypofractionated radiation therapy for stage I non-small cell lung cancer.
    Zimmermann FB; Geinitz H; Schill S; Grosu A; Schratzenstaller U; Molls M; Jeremic B
    Lung Cancer; 2005 Apr; 48(1):107-14. PubMed ID: 15777977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent end-phase boost high-dose radiation therapy for non-small-cell lung cancer with or without cisplatin chemotherapy.
    Graham PH; Clark C; Abell F; Browne L; Capp A; Clingan P; De Sousa P; Fox C; Links M
    Australas Radiol; 2006 Aug; 50(4):342-8. PubMed ID: 16884421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective study of whether radiation pneumonitis is influenced by low-dose irradiated lung volume in primary lung cancer with chronic pulmonary disease.
    Niibe Y; Hayakawa K; Masuda N; Yoshimura H
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):213-6. PubMed ID: 17301529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma.
    Rosenzweig KE; Fox JL; Yorke E; Amols H; Jackson A; Rusch V; Kris MG; Ling CC; Leibel SA
    Cancer; 2005 May; 103(10):2118-27. PubMed ID: 15830346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of intensity-modulated radiation therapy as a boost treatment on the lung-dose distributions for non-small-cell lung cancer.
    Choi Y; Kim JK; Lee HS; Hur WJ; Chai GY; Kang KM
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):683-9. PubMed ID: 15927412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.
    Liao Z; Komaki R; Milas L; Yuan C; Kies M; Chang JY; Jeter M; Guerrero T; Blumenschien G; Smith CM; Fossella F; Brown B; Cox JD
    Clin Cancer Res; 2005 May; 11(9):3342-8. PubMed ID: 15867233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of high-dose three-dimensional radiation therapy in the treatment of localised non-small-cell lung cancer.
    Bellière A; Girard N; Chapet O; Khodri M; Kubas A; Souquet PJ; Mornex F
    Cancer Radiother; 2009 Jul; 13(4):298-304. PubMed ID: 19525134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.
    Allen AM; Czerminska M; Jänne PA; Sugarbaker DJ; Bueno R; Harris JR; Court L; Baldini EH
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):640-5. PubMed ID: 16751058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer.
    Belani CP; Wang W; Johnson DH; Wagner H; Schiller J; Veeder M; Mehta M;
    J Clin Oncol; 2005 Jun; 23(16):3760-7. PubMed ID: 15837967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: a phase II trial.
    De Ruysscher D; Bremer RH; Koppe F; Wanders S; van Haren E; Hochstenbag M; Geeraedts W; Pitz C; Simons J; ten Velde G; Dohmen J; Snoep G; Boersma L; Verschueren T; van Baardwijk A; Dehing C; Pijls M; Minken A; Lambin P
    Radiother Oncol; 2006 Sep; 80(3):307-12. PubMed ID: 16949169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New approaches to radiotherapy as definitive treatment for inoperable lung cancer.
    Berman AT; Rengan R
    Semin Thorac Cardiovasc Surg; 2008; 20(3):188-97. PubMed ID: 19038727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose escalation in the radiotherapy of non-small-cell lung cancer with aperture-based intensity modulation and photon beam energy optimization for non-preselected patients.
    St-Hilaire J; Sévigny C; Beaulieu F; Germain F; Lavoie C; Dagnault A; Gingras L; Tremblay D; Beaulieu L
    Radiother Oncol; 2009 Jun; 91(3):342-8. PubMed ID: 19135749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study.
    Hata M; Tokuuye K; Kagei K; Sugahara S; Nakayama H; Fukumitsu N; Hashimoto T; Mizumoto M; Ohara K; Akine Y
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):786-93. PubMed ID: 17379439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.